Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04750629 · ClinicalTrials.gov registry record

Clinical Evaluation of a Point-of-Care (POC), COVID-19 Rapid Antigen Test (CoviDx™)

A clinical trial of Covid19 and SARS-CoV-2, sponsored by Lumos Diagnostics.

Completed
Registry status
140
Enrollment target
2
Study locations

NCT04750629 is a study of Covid19 and SARS-CoV-2 that has completed, run by Lumos Diagnostics. The registered enrollment target is 140 participants, below the 2,701-participant average among 94 other Covid19 trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04750629, a study of Covid19 and SARS-CoV-2, has completed, sponsored by Lumos Diagnostics.

COMPLETED
Registry status
140 participants
Enrollment target
2
Study locations

Study Summary

Prospective study that will evaluate the clinical agreement of the CoviDx™ Rapid Antigen test compared to SARS-CoV-2 RT-PCR.

Conditions Studied

Interventions

  • DEVICE POC CoviDx™ Rapid Antigen Test

Study Locations (2)

Florida

  • Doral Medical Research - Hialeah
  • Comprehensive Clinical Research - West Palm Beach

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2021-02-08
Est. Completion 2021-05-14

Sponsor

Lumos Diagnostics

6 total trials

What the Registry Record Tells You About NCT04750629

The ClinicalTrials.gov registry entry for NCT04750629 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,701-participant average among 94 other Covid19 trials with a reported enrollment target (95% lower). The listed sponsor is Lumos Diagnostics, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Covid19 appearing as the primary indexed condition, and to 1 intervention - of which POC CoviDx™ Rapid Antigen Test is the first listed.

NCT04750629 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT04750629 about?

NCT04750629 is a clinical study titled "Clinical Evaluation of a Point-of-Care (POC), COVID-19 Rapid Antigen Test (CoviDx™)". Prospective study that will evaluate the clinical agreement of the CoviDx™ Rapid Antigen test compared to SARS-CoV-2 RT-PCR.

What is the current status of trial NCT04750629?

This trial is currently completed. The enrollment target is 140 participants. The study started on 2021-02-08. Estimated completion is 2021-05-14.

What conditions does trial NCT04750629 study?

This clinical trial studies the following conditions: Covid19, SARS-CoV-2.

What interventions are being tested in trial NCT04750629?

The interventions under investigation include: POC CoviDx™ Rapid Antigen Test (DEVICE).

Who is sponsoring clinical trial NCT04750629?

This trial is sponsored by Lumos Diagnostics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04750629 being conducted?

This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Covid19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.